Company intelligence / Profile preview
Receptor Life Sciences
Seattle, Washington, United Statesreceptorlife.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Receptor Life Sciences has advanced its lead candidate, RLS103—an inhaled dry powder cannabidiol (CBD) formulation—into clinical trials targeting acute psychiatric and neurological disorders. The company recently secured $9.7 million in Series A1 financing to support these efforts. The IND for RLS103 has been accepted by the FDA, with first-in-human studies initiated. The product aims to address significant unmet needs in acute anxiety treatment with a rapid-onset cannabinoid therapy delivered via inhalation.
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Small molecules (cannabinoids)Drug/device combination products (inhaled and oral formulations)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Granite Point Capital led recent financing round; no major pharma partnerships disclosed as of latest updates
Beyond the preview
Go deeper on Receptor Life Sciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Receptor Life Sciences.